Loading
companiesCompany
Ambagon Therapeutics
Ambagon Therapeutics designs small molecules that act like glue, locking a hub protein called 14-3-3 onto its partner proteins to switch them on or off. It is an early-stage company with cancer and brain disease programmes.
Overview
Ambagon Therapeutics calls itself the 14-3-3 molecular glue company: it develops small-molecule stabilisers of 14-3-3:client protein complexes to modulate intrinsically disordered proteins and transcription factors, using a 14-3-3 structural 'encyclopedia', a dedicated compound library and high-throughput X-ray crystallography. The pipeline lists a neurodegeneration kinase programme in lead optimisation, an oncology programme against a transcription factor and structural protein at hit exploration, and metabolic and neurology programmes; in April 2026 Symeres announced a collaboration with Ambagon on molecular glues in colorectal cancer. All programmes are preclinical. Incorporated in 2020 with a San Francisco address, its SEC Form D filings record about 7.2 million US dollars sold in 2020, 45 million in 2022 and 5 million in 2025, the last listing Eindhoven, Netherlands, the only location on its contact page.
Headquarters
Eindhoven, NL
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Form D offering · Total sold of a 12 million US dollar offering per Form D filed February 2025; issuer address given as Eindhoven | 2025 | $5M | sec.gov |
| Form D offering · Total sold of an 85 million US dollar offering per amended Form D filed June 2022 | 2022 | $45M | sec.gov |
| Form D offering · Total sold per Form D filed August 2020 | 2020 | $7M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Founded
2020
Notes
top- The hint said South San Francisco; earlier Form D filings list San Francisco, but the website contact page lists only Eindhoven, so HQ is recorded as Eindhoven, NL. Series names and investors not disclosed in fetched sources. The 2022 offering is widely reported as a Series A but that label was not verified. The domain ambagon.com is a parked domain; the company site is ambagontx.com.